219 related articles for article (PubMed ID: 37443111)
21. RNA binding protein CUGBP2/CELF2 mediates curcumin-induced mitotic catastrophe of pancreatic cancer cells.
Subramaniam D; Ramalingam S; Linehan DC; Dieckgraefe BK; Postier RG; Houchen CW; Jensen RA; Anant S
PLoS One; 2011 Feb; 6(2):e16958. PubMed ID: 21347286
[TBL] [Abstract][Full Text] [Related]
22. Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line.
Lu YY; Jing DD; Xu M; Wu K; Wang XP
World J Gastroenterol; 2008 Sep; 14(35):5403-11. PubMed ID: 18803351
[TBL] [Abstract][Full Text] [Related]
23.
Kuang W; Wang X; Ding J; Li J; Ji M; Chen W; Wang L; Yang P
Front Immunol; 2022; 13():805311. PubMed ID: 35154122
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases.
Solorzano CC; Baker CH; Bruns CJ; Killion JJ; Ellis LM; Wood J; Fidler IJ
Cancer Biother Radiopharm; 2001 Oct; 16(5):359-70. PubMed ID: 11776753
[TBL] [Abstract][Full Text] [Related]
25. Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice.
Bruns CJ; Shrader M; Harbison MT; Portera C; Solorzano CC; Jauch KW; Hicklin DJ; Radinsky R; Ellis LM
Int J Cancer; 2002 Nov; 102(2):101-8. PubMed ID: 12385004
[TBL] [Abstract][Full Text] [Related]
26. Molecular basis of the synergistic antiangiogenic activity of bevacizumab and mithramycin A.
Jia Z; Zhang J; Wei D; Wang L; Yuan P; Le X; Li Q; Yao J; Xie K
Cancer Res; 2007 May; 67(10):4878-85. PubMed ID: 17510417
[TBL] [Abstract][Full Text] [Related]
27. Gene therapy for pancreatic cancer using an adenovirus vector encoding soluble flt-1 vascular endothelial growth factor receptor.
Hoshida T; Sunamura M; Duda DG; Egawa S; Miyazaki S; Shineha R; Hamada H; Ohtani H; Satomi S; Matsuno S
Pancreas; 2002 Aug; 25(2):111-21. PubMed ID: 12142732
[TBL] [Abstract][Full Text] [Related]
28. Long non-coding RNA SNHG17 contributes to the progression of pancreatic adenocarcinoma by modulating miR-32-5p/EZH2/STAT3 signaling.
Ying L; Wang J; Feng J; Wu Z
Mol Biol Rep; 2023 Jul; 50(7):5941-5947. PubMed ID: 37253918
[TBL] [Abstract][Full Text] [Related]
29. Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma.
Shi Q; Le X; Abbruzzese JL; Peng Z; Qian CN; Tang H; Xiong Q; Wang B; Li XC; Xie K
Cancer Res; 2001 May; 61(10):4143-54. PubMed ID: 11358838
[TBL] [Abstract][Full Text] [Related]
30. Dual oxidase 2 and pancreatic adenocarcinoma: IFN-γ-mediated dual oxidase 2 overexpression results in H2O2-induced, ERK-associated up-regulation of HIF-1α and VEGF-A.
Wu Y; Meitzler JL; Antony S; Juhasz A; Lu J; Jiang G; Liu H; Hollingshead M; Haines DC; Butcher D; Panter MS; Roy K; Doroshow JH
Oncotarget; 2016 Oct; 7(42):68412-68433. PubMed ID: 27637085
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic inhibition of Sp1 expression in growing tumors by mithramycin a correlates directly with potent antiangiogenic effects on human pancreatic cancer.
Yuan P; Wang L; Wei D; Zhang J; Jia Z; Li Q; Le X; Wang H; Yao J; Xie K
Cancer; 2007 Dec; 110(12):2682-90. PubMed ID: 17973266
[TBL] [Abstract][Full Text] [Related]
32. STAT3-targeting RNA interference inhibits pancreatic cancer angiogenesis in vitro and in vivo.
Huang C; Jiang T; Zhu L; Liu J; Cao J; Huang KJ; Qiu ZJ
Int J Oncol; 2011 Jun; 38(6):1637-44. PubMed ID: 21479358
[TBL] [Abstract][Full Text] [Related]
33. Differential vascular and transcriptional responses to anti-vascular endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts.
Bockhorn M; Tsuzuki Y; Xu L; Frilling A; Broelsch CE; Fukumura D
Clin Cancer Res; 2003 Sep; 9(11):4221-6. PubMed ID: 14519649
[TBL] [Abstract][Full Text] [Related]
34. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
35. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.
Bruns CJ; Harbison MT; Davis DW; Portera CA; Tsan R; McConkey DJ; Evans DB; Abbruzzese JL; Hicklin DJ; Radinsky R
Clin Cancer Res; 2000 May; 6(5):1936-48. PubMed ID: 10815919
[TBL] [Abstract][Full Text] [Related]
36. Effect of endothelial PAS domain protein 1 and hypoxia inducible factor 1alpha on vascular endothelial growth factor expression in human pancreatic carcinoma.
Zhu DM; Li DC; Zhang ZX; Zhang XY
Chin Med J (Engl); 2008 Nov; 121(22):2258-64. PubMed ID: 19080330
[TBL] [Abstract][Full Text] [Related]
37. Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression.
Itakura J; Ishiwata T; Friess H; Fujii H; Matsumoto Y; Büchler MW; Korc M
Clin Cancer Res; 1997 Aug; 3(8):1309-16. PubMed ID: 9815813
[TBL] [Abstract][Full Text] [Related]
38. C-X-C motif chemokine receptor 4 promotes tumor angiogenesis in gastric cancer via activation of JAK2/STAT3.
Zhang Q; Xu F; Shi Y; Chen YW; Wang HP; Yu X; Li Y
Cell Biol Int; 2017 Aug; 41(8):854-862. PubMed ID: 28544312
[TBL] [Abstract][Full Text] [Related]
39. FOSL2 promotes VEGF-independent angiogenesis by transcriptionnally activating Wnt5a in breast cancer-associated fibroblasts.
Wan X; Guan S; Hou Y; Qin Y; Zeng H; Yang L; Qiao Y; Liu S; Li Q; Jin T; Qiu Y; Liu M
Theranostics; 2021; 11(10):4975-4991. PubMed ID: 33754039
[TBL] [Abstract][Full Text] [Related]
40. Lipocalin 2 is a novel regulator of angiogenesis in human breast cancer.
Yang J; McNeish B; Butterfield C; Moses MA
FASEB J; 2013 Jan; 27(1):45-50. PubMed ID: 22982376
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
